Most practitioners order an HbA1c and read 5.8 as normal. The standard reference range calls it fine. The patient gains another twelve pounds, reports unrelenting fatigue, and returns six months later at 6.2. By that point, insulin resistance has been progressing for years. The Kharrazian Institute's clinical training on blood sugar regulation disorders teaches practitioners to intercept this trajectory well before the conventional threshold — because early stage diabetes detection depends on how you read the number, not just whether the number flags.
Dr. Datis Kharrazian's coursework emphasizes a functional interpretation of HbA1c alongside a cluster of supporting markers that together tell a more complete metabolic story. The goal is identifying dysglycemia patterns early enough that dietary and lifestyle interventions can still reverse the trajectory.
Why Standard HbA1c Ranges Miss Early Stage Diabetes Detection
The conventional HbA1c cutoffs were built to identify disease, not prevent it. A result under 5.7 is labeled normal. A result between 5.7 and 6.4 is called pre-diabetic. Diabetes is diagnosed at 6.5 or above. What those cutoffs don't capture is the metabolic damage already accumulating in the 5.5 to 5.7 range — a zone where chronic glycation and oxidative stress are already active and insulin resistance is often well-established.
Functional medicine research supports a tighter window. Dr. Kharrazian's clinical training uses a functional range of approximately 4.8 to 5.4 for HbA1c. A result at 5.5 or higher warrants a clinical conversation about glucose metabolism, even when the standard lab report prints "within normal limits." Waiting for 5.7 to act means waiting for a process that has already been running for years.
This distinction is the practical core of early stage diabetes detection: the question is not whether the patient has crossed into a labeled disease category, but whether their metabolic physiology is trending in a direction that will get them there.
What HbA1c Actually Measures — and Where It Falls Short
HbA1c reflects average blood glucose over approximately 90 days by measuring glycated hemoglobin. The higher the chronic blood glucose, the more hemoglobin gets glycated. It's a reliable marker of sustained glucose exposure, but it has meaningful limitations.
Hemolytic anemia, certain hemoglobin variants, and iron deficiency can all distort HbA1c values independently of actual glucose metabolism. A patient with iron-deficiency anemia may read a falsely elevated HbA1c. A patient with hemolytic conditions may read falsely low. Before acting on the number, the practitioner needs to know whether the measurement itself is reliable for that individual.
HbA1c also misses postprandial spikes. A patient can maintain a borderline HbA1c while spiking to 180 mg/dL after every meal. Two-hour postprandial glucose and fasting insulin add the context HbA1c alone doesn't provide.
The glucose metabolism assessment taught in Dr. Kharrazian's coursework treats HbA1c as one data point in a cluster, not a standalone verdict.
Supporting Markers That Complete the Metabolic Picture
C-peptide is produced in equal amounts to insulin during endogenous insulin synthesis — it's a direct read on how hard the beta cells are working. Elevated fasting C-peptide indicates insulin hypersecretion, a hallmark of peripheral insulin resistance. The pancreas is compensating. Diminished C-peptide in a hyperglycemic patient suggests beta-cell exhaustion or autoimmune destruction. The treatment direction is entirely different depending on which pattern is present.
Pancreatic islet cell antibodies — including anti-GAD65, anti-IA2, and zinc transporter 8 antibodies — identify autoimmune destruction of beta cells. When these are positive in a patient with elevated HbA1c, the clinical picture shifts from metabolic insulin resistance to early-stage type 1 or LADA (latent autoimmune diabetes in adults). LADA is routinely misclassified as type 2 diabetes, and the management approaches are not interchangeable. Islet cell antibody testing belongs in the workup of any adult patient with unexplained glucose dysregulation.
Fasting insulin completes the initial panel. Fasting insulin above 8-10 µIU/mL, even with a normal fasting glucose, indicates insulin resistance. Research in endocrinology consistently shows that fasting insulin rises years before fasting glucose becomes abnormal. The pancreas compensates by oversecreating insulin, keeping glucose in range while the underlying resistance worsens. Catching elevated fasting insulin in the presence of normal glucose is one of the clearest early-stage opportunities in metabolic medicine.
Additional markers worth considering in complex cases include fasting triglycerides, HDL cholesterol, uric acid, and high-sensitivity CRP. These reflect the downstream metabolic consequences of chronic insulin resistance and inform the severity assessment.
Recognizing Dysglycemia Patterns in Clinical Presentation
Laboratory values don't exist in isolation. Pre-diabetes weight gain, particularly central adiposity that resists dietary changes, is a consistent clinical feature of insulin resistance. Fatigue after meals, strong carbohydrate cravings, difficulty losing weight despite caloric restriction, brain fog in the afternoon, and waking at 2 to 3 a.m. are all symptoms of glucose metabolism disruption.
The symptom picture also helps distinguish between two distinct dysglycemia patterns: hyperglycemia-dominant and hypoglycemia-dominant. The hyperglycemic patient often reports postprandial sedation, weight gain, and elevated thirst. The hypoglycemic patient typically reports shakiness, anxiety, and irritability between meals — symptoms that resolve with eating. Both patterns indicate dysregulation, and both can be present in the same patient at different times of day.
Dr. Kharrazian's clinical training teaches practitioners to map the symptom pattern against the laboratory findings to determine where the patient falls on the dysglycemia spectrum. That assessment drives the intervention sequence. A patient with reactive hypoglycemia and normal fasting glucose needs a different immediate intervention than a patient with elevated fasting insulin and central adiposity.
Clinical Intervention Sequence Based on Severity
The first intervention priority is blood sugar stabilization. Before asking a patient to engage in intermittent fasting, caloric restriction, or any intensive dietary protocol, their blood sugar needs to be regulated enough that they can execute the change without triggering a hypoglycemic crisis or a stress response. A patient with reactive hypoglycemia who attempts intermittent fasting prematurely will feel profoundly worse. They'll abandon the protocol and conclude that dietary intervention doesn't work for them.
Stabilizing blood sugar first means addressing meal timing and macronutrient composition. Consistent meals with adequate protein and fat at each sitting reduce postprandial spikes and prevent hypoglycemic troughs. This isn't a therapeutic destination; it's the clinical prerequisite that makes deeper intervention feasible.
Once stability is established, the intervention complexity can increase based on the severity assessment:
- Mild dysglycemia (borderline HbA1c, mildly elevated fasting insulin, no antibodies): Dietary modification focused on carbohydrate quality and meal composition, resistance exercise, sleep optimization, and stress physiology support.
- Moderate dysglycemia (HbA1c 5.5–6.1, elevated fasting insulin, pre-diabetes weight gain, symptomatic): Consider time-restricted eating or ketogenic dietary strategies once blood sugar is stable, targeted nutraceutical support (berberine, alpha-lipoic acid, chromium, magnesium), and continued monitoring every 60–90 days.
- Severe dysglycemia or autoimmune involvement: Islet cell antibody-positive patients require a different clinical track — addressing immune dysregulation and gut barrier function, not just metabolic intervention. Referral coordination with an endocrinologist is appropriate when LADA is suspected.
The nutraceutical support in moderate cases is evidence-informed, not speculative. Research in metabolic medicine demonstrates berberine's ability to activate AMPK and improve insulin sensitivity through mechanisms comparable to metformin. Alpha-lipoic acid improves glucose uptake via GLUT4 translocation. These are not adjuncts to add because they seem helpful; they're agents with specific mechanisms relevant to the pathophysiology being addressed.
HbA1c Interpretation Guidelines in Ongoing Monitoring
Early intervention means nothing without a monitoring strategy. Re-testing HbA1c every 90 days during active intervention gives a direct read on whether the glycation trajectory is reversing. Fasting insulin should trend down as insulin resistance improves. C-peptide normalization indicates beta-cell recovery.
Continuous glucose monitors (CGMs) have become accessible outside the diabetic population and offer a level of granularity that quarterly HbA1c cannot. A two-week CGM trial shows how the patient's glucose behaves around specific foods, under stress, and during sleep. That data closes the interpretive gap that HbA1c leaves open.
Practitioners using a functional HbA1c interpretation model need to document their clinical rationale clearly. A result of 5.5 flagged as clinically significant — when the standard range calls it normal — requires that the practitioner can articulate why the tighter threshold matters for that patient's presentation. Dr. Kharrazian's coursework builds that clinical reasoning into the HbA1c interpretation guidelines it teaches, giving practitioners the evidence base to support their clinical decisions.
Key Takeaways
- A functional HbA1c range of 4.8–5.4 identifies metabolic dysfunction years before standard cutoffs flag pre-diabetes.
- Fasting insulin rises before fasting glucose becomes abnormal — it is one of the earliest detectable signs of insulin resistance.
- C-peptide and islet cell antibodies distinguish metabolic insulin resistance from autoimmune beta-cell destruction, which require different clinical approaches.
- Blood sugar stabilization through meal timing and macronutrient composition must precede more intensive dietary interventions like intermittent fasting.
- Ongoing monitoring with HbA1c, fasting insulin, and C-peptide every 90 days tracks whether the intervention is reversing the trajectory.
Frequently Asked Questions
Functional medicine guidelines suggest a tighter range of 4.8–5.4. A result at 5.5 or above warrants clinical attention even when standard lab reference ranges report it as normal, particularly when paired with elevated fasting insulin or symptomatic patterns.
Fasting insulin elevates years before fasting glucose becomes abnormal. The pancreas compensates by oversecreating insulin to maintain glucose levels. Catching this early — before HbA1c has shifted — is one of the most actionable windows in metabolic medicine.
LADA (latent autoimmune diabetes in adults) is autoimmune beta-cell destruction that presents in adulthood and is frequently misclassified as type 2 diabetes. Islet cell antibody testing — anti-GAD65, anti-IA2, ZnT8 — identifies it. Management differs significantly from metabolic insulin resistance.
Patients with reactive hypoglycemia who attempt fasting protocols prematurely experience stress responses and hypoglycemic episodes that make the intervention unsustainable. Stabilizing glucose with consistent meals and adequate protein first makes intensive dietary protocols both tolerable and effective.
Every 90 days during active intervention, since HbA1c reflects a 90-day average. Pairing it with fasting insulin and C-peptide at each interval gives a fuller picture of whether insulin sensitivity and beta-cell function are improving.
About the Author
Dr. Datis Kharrazian, PhD, DHSc, DC, MS, MMSc, FACN is a Harvard Medical School research fellow and researcher at Massachusetts General Hospital's Department of Neurology, specializing in autoimmunity and neuroimmunology. He serves as Associate Clinical Professor at Loma Linda University School of Medicine and is the author of Why Do I Still Have Thyroid Symptoms When My Lab Tests Are Normal and Why Isn't My Brain Working. He is a Fellow of the American College of Nutrition, Diplomate of the Board of Nutrition Specialists, member of the American Association of Immunologists, and Fellow of the Royal Society of Medicine (UK). The Kharrazian Institute serves more than 5,000 physicians and healthcare providers worldwide.
Clinical Training in Blood Sugar Regulation
The Kharrazian Institute offers practitioner training in glucose metabolism assessment, functional lab interpretation, and clinical strategies for dysglycemia. Visit the KI course library to review current programs on metabolic and blood sugar regulation disorders.
